• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

见解:一种用于对医学和疫苗安全性真实世界证据的标准化观察性数据源进行适用性评估和质量评估的工具。

INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Standardized Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety.

作者信息

Hoxhaj Vjola, Andaur Navarro Constanza L, Riera-Arnau Judit, Elbers Roel J H J, Alsina Ema, Dodd Caitlin, Sturkenboom Miriam C J M

机构信息

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Clinical Pharmacology Service, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.

出版信息

Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70089. doi: 10.1002/pds.70089.

DOI:10.1002/pds.70089
PMID:39805807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11730612/
Abstract

PURPOSE

To describe the development of INSIGHT, a real-world data quality tool to assess completeness, consistency, and fitness-for-purpose of observational health data sources.

METHODS

We designed a three-level pipeline with data quality assessments (DQAs) to be performed in ConcePTION Common Data Model (CDM) instances. The pipeline has been coded using R.

RESULTS

INSIGHT is an open-source tool that identifies potential data quality issues in CDM-standardized instances through the systematic execution and summary of over 588 configurable DQAs. Level 1 focuses on conformance to the ConcePTION CDM specifications. Level 2 evaluates the temporal plausibility of events and uniqueness of records. Level 3 provides an overview of distributions, outliers, and trends over time to facilitate fit-for-purpose evaluation. Therefore, level 1 and 2 assure a proper data standardization, while level 3 provides information regarding the study population, and potential sub-populations. The DQAs are run locally and assessed centrally by a data quality revisor together with the data access provider's representatives.

DISCUSSION

Data quality is the sum of several internal and external features of the data. While DQAs can provide reassurance about fitness-for-purpose for secondary-use data sources, improvements in data collection are essential to reduce errors and enhance overall data quality for Real World Evidence.

CONCLUSION

INSIGHT aims to support clinical and regulatory decision-making for medicines and vaccines by evaluating the quality of observational health data sources to support fit for purpose assessment. Assessing and improving data quality will enhance the reliability and quality of the generated evidence.

STUDY REGISTRATION

This research was registered in EU PAS registration with number EU50142.

摘要

目的

描述INSIGHT的开发情况,这是一种用于评估观察性健康数据源的完整性、一致性和适用性的真实世界数据质量工具。

方法

我们设计了一个三级流程,在ConcePTION通用数据模型(CDM)实例中进行数据质量评估(DQA)。该流程已使用R语言编码。

结果

INSIGHT是一个开源工具,通过系统执行和总结超过588个可配置的DQA,识别CDM标准化实例中的潜在数据质量问题。第1级侧重于符合ConcePTION CDM规范。第2级评估事件的时间合理性和记录的唯一性。第3级提供随时间的分布、异常值和趋势概述,以促进适用性评估。因此,第1级和第2级确保适当的数据标准化,而第3级提供有关研究人群和潜在亚人群的信息。DQA在本地运行,并由数据质量审核员与数据访问提供商的代表一起进行集中评估。

讨论

数据质量是数据若干内部和外部特征的总和。虽然DQA可以为二次使用数据源的适用性提供保证,但改进数据收集对于减少错误和提高真实世界证据的整体数据质量至关重要。

结论

INSIGHT旨在通过评估观察性健康数据源的质量以支持适用性评估,来支持药品和疫苗的临床及监管决策。评估和改进数据质量将提高所生成证据的可靠性和质量。

研究注册

本研究已在欧盟PAS注册,注册号为EU50142。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/b76e7be6c49d/PDS-34-e70089-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/61e8b0641aa3/PDS-34-e70089-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/24c7c583a13b/PDS-34-e70089-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/a3725517a1d4/PDS-34-e70089-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/d1736ab2a93a/PDS-34-e70089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/0603ba15a46a/PDS-34-e70089-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/b76e7be6c49d/PDS-34-e70089-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/61e8b0641aa3/PDS-34-e70089-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/24c7c583a13b/PDS-34-e70089-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/a3725517a1d4/PDS-34-e70089-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/d1736ab2a93a/PDS-34-e70089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/0603ba15a46a/PDS-34-e70089-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f27d/11730612/b76e7be6c49d/PDS-34-e70089-g002.jpg

相似文献

1
INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Standardized Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety.见解:一种用于对医学和疫苗安全性真实世界证据的标准化观察性数据源进行适用性评估和质量评估的工具。
Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70089. doi: 10.1002/pds.70089.
2
Increasing trust in real-world evidence through evaluation of observational data quality.通过评估观察性数据质量来增加对真实世界证据的信任。
J Am Med Inform Assoc. 2021 Sep 18;28(10):2251-2257. doi: 10.1093/jamia/ocab132.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
FOUNTAIN: a modular research platform for integrated real-world evidence generation.FOUNTAIN:一个用于生成综合真实世界证据的模块化研究平台。
BMC Med Res Methodol. 2024 Oct 1;24(1):224. doi: 10.1186/s12874-024-02344-w.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
iCCM data quality: an approach to assessing iCCM reporting systems and data quality in 5 African countries.iCCM 数据质量:评估非洲 5 国 iCCM 报告系统和数据质量的方法。
J Glob Health. 2019 Jun;9(1):010805. doi: 10.7189/jogh.09.010805.
7
Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review.描述药物流行病学研究中真实世界数据源的多样性:DIVERSE 范围综述。
Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5787. doi: 10.1002/pds.5787.
8
Data quality assessments stimulate improvements to health management information systems: evidence from five African countries.数据质量评估促进了卫生管理信息系统的改进:来自五个非洲国家的证据。
J Glob Health. 2019 Jun;9(1):010806. doi: 10.7189/jogh.09.010806.
9
Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018.概述:2010 年 9 月至 2018 年 12 月期间在欧洲进行的上市后研究注册的欧洲上市后研究概述。
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11.
10
The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution.GRACE 清单用于评价观察性比较有效性研究的质量:充满希望与谨慎的故事。
J Manag Care Spec Pharm. 2014 Mar;20(3):301-8. doi: 10.18553/jmcp.2014.20.3.301.

引用本文的文献

1
Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources.mRNA-1273疫苗接种后心肌炎和心包炎的临床病程、结局及危险因素:一项使用来自五个欧洲数据源的数据进行联合真实世界证据疫苗安全性研究的方案
Vaccines (Basel). 2025 Jul 16;13(7):755. doi: 10.3390/vaccines13070755.
2
A Post-Authorisation Safety Study of a Respiratory Syncytial Virus Vaccine in Pregnant Women and Their Offspring in a Real-World Setting: Generic Protocol for a Target Trial Emulation.一项在真实环境中对孕妇及其后代进行呼吸道合胞病毒疫苗的上市后安全性研究:目标试验模拟通用方案
Vaccines (Basel). 2025 Mar 5;13(3):272. doi: 10.3390/vaccines13030272.

本文引用的文献

1
From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding.从构思到 concePTION:一个支持更好地监测和沟通妊娠和哺乳期药物安全性的网络的诞生。
Clin Pharmacol Ther. 2022 Jan;111(1):321-331. doi: 10.1002/cpt.2476. Epub 2021 Nov 26.
2
Increasing trust in real-world evidence through evaluation of observational data quality.通过评估观察性数据质量来增加对真实世界证据的信任。
J Am Med Inform Assoc. 2021 Sep 18;28(10):2251-2257. doi: 10.1093/jamia/ocab132.
3
Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data.
在真实世界数据时代,通过系统的范围综述评估国家临床数据研究网络中的数据质量评估实践。
J Am Med Inform Assoc. 2020 Dec 9;27(12):1999-2010. doi: 10.1093/jamia/ocaa245.
4
ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations.ADVANCE 数据库的特征描述及其是否适用于多国关于百白破疫苗接种覆盖率、效益和风险的研究。
Vaccine. 2020 Dec 22;38 Suppl 2:B8-B21. doi: 10.1016/j.vaccine.2020.01.100. Epub 2020 Feb 12.
5
Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products.选择适用于医疗产品有效性决策的真实世界数据分析常用数据模型。
Clin Pharmacol Ther. 2020 Apr;107(4):827-833. doi: 10.1002/cpt.1577. Epub 2019 Aug 25.
6
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.欧洲的电子医疗保健数据库:特征描述及在药品监管中的应用潜力分析
BMJ Open. 2018 Sep 5;8(9):e023090. doi: 10.1136/bmjopen-2018-023090.
7
Evaluating Foundational Data Quality in the National Patient-Centered Clinical Research Network (PCORnet®).评估国家以患者为中心的临床研究网络(PCORnet®)中的基础数据质量。
EGEMS (Wash DC). 2018 Apr 13;6(1):3. doi: 10.5334/egems.199.
8
A Comparison of Data Quality Assessment Checks in Six Data Sharing Networks.六个数据共享网络中数据质量评估检查的比较
EGEMS (Wash DC). 2017 Jun 12;5(1):8. doi: 10.5334/egems.223.
9
A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data.电子健康记录数据二次使用的统一数据质量评估术语和框架。
EGEMS (Wash DC). 2016 Sep 11;4(1):1244. doi: 10.13063/2327-9214.1244. eCollection 2016.
10
The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.美国食品药品监督管理局的哨兵计划——一种全面的医疗产品监测方法。
Clin Pharmacol Ther. 2016 Mar;99(3):265-8. doi: 10.1002/cpt.320. Epub 2016 Jan 12.